FDA approves revolutionary blood cancer treatmentFDA’s approval of a new combination treatment for patients with classical Hodgkin lymphoma (cHL) is the first new advanced treatment for the disease in 40 years
Drugs in Perspective: Opdivo (nivolumab)On December 22, 2014, Opdivo (nivolumab) was approved by FDA with a breakthrough therapy designation. Nivolumab is the second human programmed death-1 (PD-1) receptor-blocking antibody to gain accelerated approval for treatment of patients with unresectable or metastatic melanoma and disease progression following Yervoy (ipilimumab) and, if BRAF V600 mutation positive, a BRAF inhibitor.
Combination treatments target advanced melanomaTreatments that combine newer targeted therapies have begun to lift the “death sentence” that advanced melanoma formerly carried, an expert says.